Vanda Pharmaceuticals Inc (VNDA)
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies aimed at addressing unmet medical needs in global markets. Its commercial portfolio includes Fanapt for acute manic or mixed episodes associated with bipolar I disorder and for schizophrenia, HETLIOZ for non-24-hour sleep-wake disorders and nighttime sleep disturbances, PONVORY for relapsing forms of multiple sclerosis, and NEREUS for the prevention of vomiting induced by motion. The company also maintains a development pipeline that includes additional formulations and candidates across psychiatry, neurology, dermatology, gastroenterology, and oncology-related areas. Vanda was incorporated in 2002 and is headquartered in Washington, District of Columbia. Its common stock is listed on NASDAQ under the symbol VNDA.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VNDA
|
$6.21
|
21.2% Upside
|
Undervalued
|
$12.19
|
138.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 4, 2026
|
1.4x
|
1.4x
|
309.6 M
|
161.8 M
|
6.9%
|
78.8%
|
-2.3
|
52.0%
|
